Screener
Ligand Pharmaceuticals LGND Capvaxive — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Kyprolis | 7,044 | 8,803 | 13,784 | 13,526 |
| Ohtuvayre | 4,144 | 2,084 | 7,131 | 3,496 |
| Rylaze | 3,201 | 2,864 | 6,422 | 5,983 |
| Capvaxive | 2,316 | 2,250 | 4,285 | 3,135 |
| Vaxneuvance | 1,351 | 2,643 | 2,961 | 3,928 |
| Teriparatide injection | 1,470 | 2,298 | 2,791 | 3,489 |
| Other | 4,269 | 2,564 | 8,030 | 6,235 |
| Revenue from intangible royalty assets | 37,362 | 30,084 | 70,293 | 51,671 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's capvaxive — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported capvaxive — total revenues and income of $2.32M in Q2 2026.
- How has Ligand Pharmaceuticals's capvaxive — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's capvaxive — total revenues and income increased by 2.9% year-over-year, from $2.25M to $2.32M.
- What does capvaxive — total revenues and income mean?
- This metric represents the aggregate financial inflows generated by the Capvaxive product line, including royalties, milestone payments, and license fees. It serves as a key indicator of the commercial adoption and market performance of this specific therapeutic asset within the company's portfolio. Tracking this revenue stream allows investors to evaluate the direct contribution of the product to the company's overall top-line growth and long-term value creation.
Ask your AI about Ligand Pharmaceuticals's capvaxive — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude